ArticleCell & bioscience2026
LncRNA HOXC-AS3 prevents chondrocyte senescence and osteoarthritis progression through miR-615-3p sponging and RRBP1 interaction.
Article in Cell & bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOsteoarthritis (OA) is a widespread chronic joint disorder characterized by progressive cartilage degeneration, leading to substantial impairment in quality of life for millions of individuals globally. Cellular senescence has been increasingly recognized as a central contributor to OA pathogenesis, with senescent chondrocytes exhibiting a senescence-associated secretory phenotype that promotes tissue destruction. Long non-coding RNAs (lncRNAs) are known to play essential roles in maintaining cartilage homeostasis; however, their regulatory functions in OA remain poorly defined. This study aimed to elucidate the expression patterns, biological roles, and molecular mechanisms of lncRNA HOXC-AS3 in chondrocyte physiology and OA development.
resultsHOXC-AS3 expression was markedly reduced in OA-affected cartilage tissues and in human chondrocytes exposed to IL-1β. Functional analyses revealed that HOXC-AS3 knockdown suppressed chondrocyte proliferation, accelerated cellular senescence, and disrupted extracellular matrix homeostasis, whereas its overexpression ameliorated IL-1β-induced chondrocyte dysfunction. Mechanistically, HOXC-AS3 operates through two distinct pathways: acting as a competing endogenous RNA by directly sequestering miR-615-3p, and physically interacting with ribosome-binding protein 1 (RRBP1). Both pathways converge to regulate the expression of citron rho-interacting serine/threonine kinase (CIT), a critical modulator of the cell cycle. Notably, CIT knockdown mimicked the phenotypic effects of HOXC-AS3 deficiency, while HOXC-AS3 overexpression preserved chondrocyte function by sustaining CIT expression under inflammatory stress.
conclusionsThis study establishes lncRNA HOXC-AS3 as a key regulator of chondrocyte homeostasis that mitigates OA progression via dual mechanisms-miR-615-3p sponging and RRBP1 interaction-both of which maintain CIT expression. These findings advance the understanding of the molecular networks underlying OA pathogenesis and underscore HOXC-AS3 and its downstream signaling axis as promising therapeutic targets for OA intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.